F118. EFFECT OF ARIPIPRAZOLE ONCE MONTHLY ON PERSONAL AND SOCIAL FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSES OF ACUTE AND LONG-TERM MAINTENANCE STUDIES

摘要

Along with control of psychotic symptoms, improved functioning is an important treatment goal in schizophrenia, particularly from the patient perspective. Efficacy of aripiprazole once-monthly 400 mg (AOM 400) in the treatment of acute exacerbation of schizophrenia was demonstrated in a randomized, placebo-controlled study (Study 291, ), in which AOM 400 significantly improved clinical symptoms and social functioning. In two randomized, controlled trials of AOM 400 as maintenance treatment in stable patients with schizophrenia, AOM 400 delayed time to, and reduced the rate of, impending relapse vs placebo or a subtherapeutic dose of AOM. In both of these relapse prevention studies, as well as a long-term, open-label extension study (Study 248; ), stability in clinical symptoms and patient functioning was maintained with long-term AOM 400 treatment. Here we report post-hoc analyses of the effect of AOM 400 on personal and social functioning from the acute setting and open-label extension studies.